Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy

Journal of Geriatric Oncology

Volumn 4, Issue 2, 2013, Pages 134-140

  Lowry, Lisa ^a,b   Smith, Paul ^b   Cunningham, David ^c   Linch, David C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aggressive; Elderly; Lymphoma; Refractory; Relapsed

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FACTORIAL ANALYSIS; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; PREDNISOLONE; PREDNISONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VINCRISTINE;

EID: 84875599967     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.12.001     Document Type: Article

References (17)

1. CRUK cancer statistics for the UK [Internet] [Accessed 23.11.2011]. http://info.cancerresearchuk.org/cancerstats/types/nhl/.
2. The Non-Hodgkin's Lymphoma Classification Project A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997, 89(11):3909-3918.
3. Cunningham D., Smith P., Mouncey P., et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma [abstract]. J Clin Oncol 2011, 29(Supplement). [Abstract 8000].
4. Gisselbrecht C., Glass B., Laurent G., et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis [abstract]. J Clin Oncol 2011, 29(Supplement). [Abstract 8004].
5. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Eng J Med 1995, 333(23):1540-1545.
6. Tirelli U., Carbone A., Monfardini S., Zagonel V. A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute. Crit Rev Oncol Hematol 2001, 37(2):153-158.
7. Bowcock S.J., Fontana V., Patrick H.E. Very poor performance status elderly patients with aggressive B cell lymphomas can benefit from intensive chemotherapy. Br J Haematol 2012, 157(3):391-393.
8. Fields P.A., Linch D.C. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 2012, 157(2):159-170.
9. Moskowitz C.H., Bertino J.R., Glassman J.R., et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999, 17(12):3776-3785.
10. Velasquez W.S., McLaughlin P., Tucker S., et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994, 12(6):1169-1176.
11. Blay J.-Y., Gomez F., Sebban C., et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998, 92(10):3562-3568.
12. Costa L.J., Micallef I.N., Inwards D.J., et al. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-r in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant 2008, 41(8):715-720.
13. Linch D.C., Smith P., Hancock B.W., et al. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000, 11(Suppl. 1):87-90.
14. Mainwaring P.N., Cunningham D., Gregory W., et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001, 97(10):2991-2997.
15. Burton C., Linch D., Hoskin P., et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer 2006, 94(6):806-813.
16. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28(27):4184-4190.
17. Martín A., Conde E., Arnan M., et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93(12):1829-1836.